Log In
Print
BCIQ
Print
Print this Print this
 

Onalta (Onalta edotreotide) (formerly OctreoTher)

  Manage Alerts
Collapse Summary General Information
Company Progenics Pharmaceuticals Inc.
DescriptionYttrium-90 radiolabeled somatostatin peptide analog
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationNeuroendocrine tumors
Indication DetailsTreat gastroenteropancreatic neuroendocrine tumor; Treat metastatic carcinoid tumors; Treat metastatic, progressive, somatostatin receptor-positive carcinoid cancer; Treat neuroendocrine tumors
Regulatory Designation

EU - Orphan Drug (Treat gastroenteropancreatic neuroendocrine tumor)

Partner

BioMedica Life Sciences S.A.; Novartis AG


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today